Biochemical Basis and Dopamine Synthesis
The key problem in Parkinson's disease is the inability of brain structures to provide an adequate level of the neurotransmitter. To understand the essence of this deficiency, we must review the normal biosynthetic cascade of this substance.
Biosynthesis proceeds in several stages involving specific enzymes:
- Tyrosine serves as the initial substrate.
- Under the action of the enzyme tyrosine hydroxylase, it is converted into DOPA.
- Next, the enzyme DOPA decarboxylase removes a carboxyl group, resulting in the formation of dopamine itself.
It is precisely the disruption of the stability of this pathway or the death of the cells where it occurs (Substantia nigra) that leads to the characteristic symptoms of the disease.
Neurotransmitter Inactivation Pathways
Normally, after dopamine has fulfilled its function, it must be degraded to prevent excessive receptor stimulation. Biochemical inactivation proceeds via two main pathways:
- Oxidative deamination. The process is catalyzed by the enzyme MAO (monoamine oxidase). This enzyme actively breaks down dopamine directly within the synaptic cleft.
- Methylation. Carried out via the enzyme COMT (catechol-O-methyltransferase).
Understanding degradation processes is critically important, as blocking these enzymes is one of the strategies of medical treatment.
Logic of Pharmacotherapy
Since the problem lies in a lack of dopamine, the initial thought might be to administer the ready-made substance into the body. However, pure dopamine is unable to cross the blood-brain barrier (BBB) from the bloodstream into the brain. Therefore, alternative biochemical pathways are utilized.
Main drug groups:
- L-DOPA (Levodopa). Acts as a metabolic precursor of dopamine. Unlike the final product, levodopa successfully crosses the BBB. Once in brain tissues, it undergoes decarboxylation and is converted into active dopamine.
- Peripheral DOPA decarboxylase inhibitors (Carbidopa). If levodopa were to convert into dopamine in the bloodstream (peripherally), it would not reach the brain and would cause systemic side effects. Carbidopa blocks this process outside the brain, preserving levodopa for the central nervous system.
- MAO inhibitors. Drugs that specifically target the MAO-B isoform. Inhibiting this enzyme slows down dopamine degradation in the synaptic cleft. As a result, the concentration of the neurotransmitter rises and its duration of action increases, effectively compensating for the initial deficiency.
Special Role of Vitamin B6
Vitamin $B_6$ acts as a crucial coenzyme for the decarboxylase enzyme that converts DOPA into dopamine.
It is used in moderate doses in therapy. However, extreme caution is required: an excess of vitamin $B_6$ can sharply accelerate the peripheral breakdown of levodopa before it penetrates the brain. To avoid this undesirable effect, vitamin $B_6$ should always be dosed with regard to therapy or combined with decarboxylase inhibitors (e.g., carbidopa).
Briefly: answers to topical questions
What are the main drug classes for treating Parkinson's disease?
Several main groups of drugs are used to treat Parkinson's disease, influencing dopamine metabolism and receptor function.
- Levodopa preparations (L-DOPA) — act as a dopamine precursor, cross the blood-brain barrier.
- Peripheral DOPA decarboxylase inhibitors (Carbidopa, Benserazide) — prevent premature peripheral catabolism of levodopa.
- Dopamine receptor agonists (Bromocriptine) — directly stimulate postsynaptic dopamine receptors.
- MAO-B inhibitors (Selegiline) — slow down dopamine breakdown in synapses and neurons.
- COMT inhibitors (Entacapone) — block levodopa and dopamine catabolism pathways.
- Dopamine reuptake inhibitors (Amantadine) — block the return of dopamine to the presynaptic terminal.
- Anticholinergics (Trihexyphenidyl) — central M-cholinergic blockers.
Imagine delivering a valuable cargo to a fortress (the brain). The cargo is L-DOPA. The guards on the road who prevent the cargo from being unpacked prematurely are Carbidopa. And MAO inhibitors are like a plug in the drain so that the water (dopamine) stays longer in the sink (synapse).
Class and exam questions
Why is dopamine itself not administered to patients as a medication?
Dopamine has a structure that prevents it from crossing the blood-brain barrier (BBB). It remains in the bloodstream and does not enter the brain where the deficiency zone is located.
Why is carbidopa added to the treatment regimen along with levodopa?
Carbidopa is a DOPA decarboxylase inhibitor that works only in the periphery. It prevents the premature conversion of levodopa to dopamine in the blood, protecting it until it penetrates the brain.
How do MAO inhibitors help in Parkinson's disease?
The MAO enzyme (especially MAO-B) destroys dopamine in synapses. By inhibiting this enzyme, we prolong the lifespan of dopamine molecules in the synaptic cleft, increasing their concentration and mitigating deficiency symptoms.
What is the danger of high doses of vitamin B6 during treatment?
Vitamin $B_6$ is a decarboxylase coenzyme. Its excess excessively stimulates the peripheral breakdown of levodopa in the blood, causing less active substance to reach the brain.
What else to study on this topic
- Detailed mechanism of tyrosine hydroxylase action
- The role of DOPA decarboxylase in the central nervous system
- Differences between MAO-A and MAO-B enzymes
- Biochemistry of the blood-brain barrier in the context of amino acid transport
- Mechanism of the methylation reaction involving COMT
Master the entire topic in the "Biochemistry" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Parkinson's Disease" and 3,616 more pages on the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 115 video lessons on the subject
Other topics in the "Amino acid metabolism" section
Free video lessons: biochemistryShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.